These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 32171288)

  • 81. A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer.
    Cristofanilli M; Johnston SR; Manikhas A; Gomez HL; Gladkov O; Shao Z; Safina S; Blackwell KL; Alvarez RH; Rubin SD; Ranganathan S; Redhu S; Trudeau ME
    Breast Cancer Res Treat; 2013 Jan; 137(2):471-82. PubMed ID: 23239151
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer.
    Iacovelli R; Cossu Rocca M; Galli L; De Giorgi U; Sabbatini R; Santoni M; Mosca A; Fornarini G; Massari F; Masini C; Bersanelli M; Biasco E; Lolli C; Guida A; Berardi R; Terrone C; Pastorino A; Ardizzoni A; Pinto C; Buti S; Nolè F; Tortora G
    Urol Oncol; 2017 Sep; 35(9):541.e7-541.e13. PubMed ID: 28572027
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Early tumor shrinkage is independently associated with improved overall survival among patients with metastatic renal cell carcinoma: a validation study using the COMPARZ cohort.
    Grünwald V; Dietrich M; Pond GR
    World J Urol; 2018 Sep; 36(9):1423-1429. PubMed ID: 29654533
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Successful re-administration of Pazopanib in a patient with metastatic renal cell carcinoma and a history of Pazopanib-induced nephrotic syndrome: a case report.
    Jeon SY; Lee NR; Yim CY
    BMC Nephrol; 2019 Jan; 20(1):1. PubMed ID: 30606155
    [TBL] [Abstract][Full Text] [Related]  

  • 85. The European Medicines Agency review of pazopanib for the treatment of advanced renal cell carcinoma: summary of the scientific assessment of the Committee for Medicinal Products for Human Use.
    Nieto M; Borregaard J; Ersbøll J; ten Bosch GJ; van Zwieten-Boot B; Abadie E; Schellens JH; Pignatti F
    Clin Cancer Res; 2011 Nov; 17(21):6608-14. PubMed ID: 21976546
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma.
    Hutson TE; Davis ID; Machiels JP; De Souza PL; Rottey S; Hong BF; Epstein RJ; Baker KL; McCann L; Crofts T; Pandite L; Figlin RA
    J Clin Oncol; 2010 Jan; 28(3):475-80. PubMed ID: 20008644
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Outcomes of Patients With Metastatic Non-Clear-Cell Renal Cell Carcinoma Treated With Pazopanib.
    Matrana MR; Baiomy A; Campbell M; Alamri S; Shetty A; Teegavarapu P; Kalra S; Xiao L; Atkinson B; Corn P; Jonasch E; Elsayes KM; Tannir NM
    Clin Genitourin Cancer; 2017 Apr; 15(2):e205-e208. PubMed ID: 27568124
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Prescribing Preferences in the First-Line Treatment for Patients With Metastatic Renal Cell Carcinoma in the United States.
    Hackshaw MD; Holmes M; Lankford M; Thomas M; Ogbonnaya A; Eaddy M
    Clin Genitourin Cancer; 2016 Oct; 14(5):e479-e487. PubMed ID: 27221141
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial.
    Mir O; Cropet C; Toulmonde M; Cesne AL; Molimard M; Bompas E; Cassier P; Ray-Coquard I; Rios M; Adenis A; Italiano A; Bouché O; Chauzit E; Duffaud F; Bertucci F; Isambert N; Gautier J; Blay JY; Pérol D;
    Lancet Oncol; 2016 May; 17(5):632-41. PubMed ID: 27068858
    [TBL] [Abstract][Full Text] [Related]  

  • 90. An updated cost-effectiveness analysis of pazopanib versus sunitinib as first-line treatment for locally advanced or metastatic renal cell carcinoma in Italy.
    Capri S; Porta C; Condorelli C; Premoli E; Khare A; Kalra M; Modi N; Ratto B
    J Med Econ; 2020 Dec; 23(12):1579-1587. PubMed ID: 33079593
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Prognostic role of the cumulative toxicity in patients affected by metastatic renal cells carcinoma and treated with first-line tyrosine kinase inhibitors.
    Iacovelli R; Verri E; Cossu Rocca M; Aurilio G; Cullurà D; de Cobelli O; Nolè F
    Anticancer Drugs; 2017 Feb; 28(2):206-212. PubMed ID: 27754995
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Impact of concomitant acid suppressive therapy on pazopanib efficacy and dose reductions in patients with metastatic renal cell carcinoma.
    Van De Sijpe G; Beuselinck B; Van Nieuwenhuyse T; Poncelet R; Bechter O; Albersen M; Roussel E; Baldewijns M; Tack J; Spriet I
    Eur J Clin Pharmacol; 2020 Sep; 76(9):1273-1280. PubMed ID: 32474662
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma.
    Barrios CH; Hernandez-Barajas D; Brown MP; Lee SH; Fein L; Liu JH; Hariharan S; Martell BA; Yuan J; Bello A; Wang Z; Mundayat R; Rha SY
    Cancer; 2012 Mar; 118(5):1252-9. PubMed ID: 21898376
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial.
    Bex A; Mulders P; Jewett M; Wagstaff J; van Thienen JV; Blank CU; van Velthoven R; Del Pilar Laguna M; Wood L; van Melick HHE; Aarts MJ; Lattouf JB; Powles T; de Jong Md PhD IJ; Rottey S; Tombal B; Marreaud S; Collette S; Collette L; Haanen J
    JAMA Oncol; 2019 Feb; 5(2):164-170. PubMed ID: 30543350
    [TBL] [Abstract][Full Text] [Related]  

  • 95. A phase II study of cediranib (AZD 2171) in treatment naive patients with progressive unresectable recurrent or metastatic renal cell carcinoma. A trial of the PMH phase 2 consortium.
    Sridhar SS; Mackenzie MJ; Hotte SJ; Mukherjee SD; Tannock IF; Murray N; Kollmannsberger C; Haider MA; Chen EX; Halford R; Wang L; Ivy SP; Moore MJ
    Invest New Drugs; 2013 Aug; 31(4):1008-15. PubMed ID: 23354849
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Pazopanib Exposure Relationship with Clinical Efficacy and Safety in the Adjuvant Treatment of Advanced Renal Cell Carcinoma.
    Sternberg CN; Donskov F; Haas NB; Doehn C; Russo P; Elmeliegy M; Baneyx G; Banerjee H; Aimone P; Motzer RJ
    Clin Cancer Res; 2018 Jul; 24(13):3005-3013. PubMed ID: 29330204
    [No Abstract]   [Full Text] [Related]  

  • 97. Phase 2 Multicenter Single-Arm Study of Second-Line Axitinib in Favorable Risk Patients with Metastatic Renal Cell Carcinoma: FavorAx.
    Tsimafeyeu I; Borisov P; Abdelgafur A; Leonenkov R; Novikova O; Guseva I; Demchenkova M; Mikhailova N; Semenov A; Yurmazov Z; Sivunova I; Ramazanova M; Gamayunov S; Kosov D; Bratslavsky G
    Target Oncol; 2019 Feb; 14(1):33-38. PubMed ID: 30607698
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Surrogacy of intermediate endpoints for overall survival in randomized controlled trials of first-line treatment for advanced soft tissue sarcoma in the pre- and post-pazopanib era: a meta-analytic evaluation.
    Tanaka K; Kawano M; Iwasaki T; Itonaga I; Tsumura H
    BMC Cancer; 2019 Jan; 19(1):56. PubMed ID: 30634944
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Folic Acid Reduces Mucositis in Metastatic Renal Cell Carcinoma Patients: A Retrospective Study.
    Fristrup N; Donskov F
    Clin Genitourin Cancer; 2019 Aug; 17(4):254-259. PubMed ID: 31101577
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Impact of Concomitant Cardiovascular Medication on Survival of Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib or Pazopanib in the First Line.
    Fiala O; Ostašov P; Rozsypalová A; Hora M; Šorejs O; Šustr J; Bendová B; Trávníček I; Filipovský J; Fínek J; Büchler T
    Target Oncol; 2021 Sep; 16(5):643-652. PubMed ID: 34363554
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.